NO20055496L - Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer - Google Patents
Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorerInfo
- Publication number
- NO20055496L NO20055496L NO20055496A NO20055496A NO20055496L NO 20055496 L NO20055496 L NO 20055496L NO 20055496 A NO20055496 A NO 20055496A NO 20055496 A NO20055496 A NO 20055496A NO 20055496 L NO20055496 L NO 20055496L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- methods
- kinase inhibitors
- derivatives
- pyrazoloquinazoline
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- GNOYRJIXSUNXIH-UHFFFAOYSA-N N1=CNC2=C3C=NN=C3C=CC2=C1 Chemical class N1=CNC2=C3C=NN=C3C=CC2=C1 GNOYRJIXSUNXIH-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Det beskrives pyrazolokinazolinderivater med formel (la) eller (lb), som definert i beskrivelsen, og farmasøytisk akseptable salter derav, fremgangsmåter for fremstilling av disse og farmasøytiske blandinger som omfatter disse. Forbindelsene kan være terapeutisk anvendelige ved behandlingen av sykdommer assosiert med feilregulert proteinkinaseaktivitet, som for eksempel cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47266103P | 2003-05-22 | 2003-05-22 | |
| PCT/EP2004/050612 WO2004104007A1 (en) | 2003-05-22 | 2004-04-27 | Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20055496D0 NO20055496D0 (no) | 2005-11-21 |
| NO20055496L true NO20055496L (no) | 2006-02-14 |
| NO334992B1 NO334992B1 (no) | 2014-08-18 |
Family
ID=33476970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20055496A NO334992B1 (no) | 2003-05-22 | 2005-11-21 | Pyrazolokinazolinderivater, metoder for deres fremstilling, mellomprodukter, farmasøytiske blandinger og sett samt deres anvendelse ved behandling av sykdom |
Country Status (36)
| Country | Link |
|---|---|
| US (9) | US7482354B2 (no) |
| EP (1) | EP1636236B1 (no) |
| JP (1) | JP5043432B2 (no) |
| KR (1) | KR101084871B1 (no) |
| CN (2) | CN1826343A (no) |
| AP (1) | AP2064A (no) |
| AR (2) | AR044543A1 (no) |
| AU (1) | AU2004240772B2 (no) |
| BR (2) | BR122019010200B8 (no) |
| CA (1) | CA2526578C (no) |
| CO (1) | CO5721006A2 (no) |
| CR (1) | CR8102A (no) |
| CY (1) | CY1114708T1 (no) |
| DK (1) | DK1636236T3 (no) |
| EA (1) | EA010904B1 (no) |
| EC (1) | ECSP056194A (no) |
| ES (1) | ES2436524T3 (no) |
| GE (1) | GEP20094664B (no) |
| HR (1) | HRP20050967B8 (no) |
| IL (1) | IL172046A (no) |
| IS (1) | IS2939B (no) |
| ME (1) | ME00142B (no) |
| MX (1) | MXPA05012573A (no) |
| MY (1) | MY142019A (no) |
| NO (1) | NO334992B1 (no) |
| NZ (1) | NZ543661A (no) |
| OA (1) | OA13170A (no) |
| PL (1) | PL1636236T3 (no) |
| PT (1) | PT1636236E (no) |
| RS (2) | RS20050944A (no) |
| SI (1) | SI1636236T1 (no) |
| TN (1) | TNSN05298A1 (no) |
| TW (1) | TWI349672B (no) |
| UA (1) | UA80763C2 (no) |
| WO (1) | WO2004104007A1 (no) |
| ZA (1) | ZA200509486B (no) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS20050944A (sr) | 2003-05-22 | 2008-06-05 | Nerviano Medical Sciences S.R.L., | Derivati pirazolo- hinazolina,postupci za njihovo dobijanje i njihova upotreba kao inhibitora kinaze |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| EP1694686A1 (en) | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
| US7772232B2 (en) | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
| ITMI20041033A1 (it) | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Composti farmaceutici |
| JP2008510734A (ja) | 2004-08-18 | 2008-04-10 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP1986632B1 (en) * | 2006-02-10 | 2012-08-15 | Nerviano Medical Sciences S.R.L. | Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic |
| EP2026800A1 (en) * | 2006-05-09 | 2009-02-25 | Novartis AG | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
| US20080015193A1 (en) * | 2006-06-20 | 2008-01-17 | Mendoza Jose S | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof |
| US7517882B2 (en) * | 2006-09-18 | 2009-04-14 | Polaris Group | Protein kinase inhibitors |
| JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
| UA102219C2 (ru) * | 2006-12-21 | 2013-06-25 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы |
| SI2125822T1 (sl) * | 2006-12-21 | 2015-01-30 | Nerviano Medical Sciences S.R.L. | Substituirani pirazolo-kinazolinski derivati, postopek za njihovo pripravo in njihova uporaba kot inhibitorji kinaze |
| EP2213673B1 (en) | 2007-10-23 | 2013-06-05 | Msd K.K. | Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
| US8841312B2 (en) * | 2007-12-19 | 2014-09-23 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| JP5530422B2 (ja) * | 2008-04-07 | 2014-06-25 | アムジエン・インコーポレーテツド | 細胞周期阻害薬としてのｇｅｍ−二置換およびスピロ環式アミノピリジン／ピリミジン |
| TWI426074B (zh) * | 2008-04-30 | 2014-02-11 | Nerviano Medical Sciences Srl | ５－（２－胺基－嘧啶－４－基）－２－芳基－１ｈ－吡咯－３－羧醯胺之製造方法 |
| WO2009156315A1 (en) * | 2008-06-26 | 2009-12-30 | Nerviano Medical Sciences S.R.L. | Pyrazolo-quinazolines |
| CN102105152B (zh) | 2008-07-29 | 2012-10-17 | 内尔维阿诺医学科学有限公司 | 包含cdks抑制剂和抗肿瘤剂的治疗组合 |
| US8946226B2 (en) * | 2008-07-29 | 2015-02-03 | Nerviano Medical Sciences S.R.L. | Use of CDK inhibitor for the treatment of glioma |
| US8653097B2 (en) * | 2008-10-17 | 2014-02-18 | Boehringer Ingelheim International Gmbh | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (P13-kinases) inhibitor |
| US8912194B2 (en) * | 2008-11-24 | 2014-12-16 | Nerviano Medical Sciences S.R.L. | CDK inhibitor for the treatment of mesothelioma |
| IT1395724B1 (it) * | 2009-02-25 | 2012-10-19 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
| JP5650193B2 (ja) * | 2009-03-20 | 2015-01-07 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 胸腺腫の治療のためのキナーゼ阻害剤の使用 |
| US9243000B2 (en) | 2009-04-22 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Thia-triaza-indacenes |
| ES2660146T3 (es) | 2009-04-29 | 2018-03-21 | Nerviano Medical Sciences S.R.L. | Sales del inhibidor de cdk |
| AR076784A1 (es) | 2009-05-26 | 2011-07-06 | Nerviano Medical Sciences Srl | Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico |
| CN103626777B (zh) * | 2009-07-29 | 2015-10-21 | 内尔维阿诺医学科学有限公司 | Plk抑制剂的盐类 |
| CN102844313B (zh) * | 2010-01-28 | 2016-10-05 | 哈佛大学校长及研究员协会 | 提高蛋白酶体活性的组合物和方法 |
| US8735386B2 (en) * | 2010-07-23 | 2014-05-27 | Boehringer Ingelheim International Gmbh | Aminopyrazoloquinazolines |
| JP5997143B2 (ja) * | 2010-07-30 | 2016-09-28 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | タンパク質キナーゼ活性の調整剤としてのイソオキサゾロ−キナゾリン |
| EP2619181A1 (en) | 2010-09-23 | 2013-07-31 | Syngenta Participations AG | Novel microbiocides |
| HRP20161092T1 (hr) * | 2010-10-25 | 2016-10-21 | G1 Therapeutics, Inc. | Cdk inhibitori |
| CA2812223C (en) * | 2010-12-17 | 2019-03-12 | Nerviano Medical Sciences S.R.L. | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors |
| EP2668190B1 (en) * | 2011-01-26 | 2016-08-17 | Nerviano Medical Sciences S.r.l. | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors |
| WO2012101029A1 (en) * | 2011-01-26 | 2012-08-02 | Nerviano Medical Sciences S.R.L. | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors |
| WO2012117021A2 (en) | 2011-03-03 | 2012-09-07 | Syngenta Participations Ag | Novel microbiocidal oxime ethers |
| MY161199A (en) | 2011-03-23 | 2017-04-14 | Amgen Inc | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| US9556166B2 (en) | 2011-05-12 | 2017-01-31 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
| WO2013092460A1 (en) | 2011-12-20 | 2013-06-27 | Syngenta Participations Ag | Cyclic bisoxime microbicides |
| JP6128133B2 (ja) * | 2012-01-23 | 2017-05-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｇｆ−１ｒ／ｉｒ阻害剤としての５，８−ジヒドロ−６ｈ−ピラゾロ［３，４−ｈ］キナゾリン |
| EP2641901A1 (en) | 2012-03-22 | 2013-09-25 | Syngenta Participations AG. | Novel microbiocides |
| ES2755772T3 (es) | 2012-11-07 | 2020-04-23 | Nerviano Medical Sciences Srl | Pirimidinil y piridinilpirrolopiridinonas sustituidas, proceso para su preparación y su uso como inhibidores de cinasas |
| WO2014116228A1 (en) | 2013-01-25 | 2014-07-31 | President And Fellows Of Harvard College | Usp14 inhibitors for treating or preventing viral infections |
| CN105407723A (zh) | 2013-03-15 | 2016-03-16 | G1治疗公司 | 高效的抗赘生剂和抗增生剂 |
| WO2014144326A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient protection of normal cells during chemotherapy |
| WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| CA2944610C (en) | 2014-04-07 | 2024-01-09 | Netherlands Translational Research Center B.V. | (5,6-dihydro)pyrimido[4,5-e]indolizines |
| US20150297606A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
| ES2873959T3 (es) | 2014-05-28 | 2021-11-04 | Piramal Entpr Ltd | Combinación farmacéutica que comprende un inhibidor de CDK y un inhibidor de tiorredoxina reductasa para el tratamiento del cáncer |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| WO2016040858A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| CA2992161A1 (en) | 2015-07-17 | 2017-01-26 | Institut Pasteur | 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation |
| WO2018011382A1 (en) | 2016-07-15 | 2018-01-18 | Institut Pasteur | 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair |
| DK3505519T3 (da) * | 2016-11-11 | 2022-02-07 | Yangtze River Pharm Group Co | Pyridinamin-substituerede heterotricyclo-forbindelser, fremstilling deraf og anvendelse i medicin |
| US11117901B2 (en) | 2017-07-11 | 2021-09-14 | Nerviano Medical Sciences S.R.L. | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors |
| CN107383019B (zh) * | 2017-07-28 | 2019-10-15 | 江苏艾凡生物医药有限公司 | 吡唑并[4,3-h]喹唑啉类化合物及其用途 |
| KR102464677B1 (ko) * | 2017-08-11 | 2022-11-10 | 셍커 파마슈티컬스 (지앙수) 엘티디. | 단백질 인산화효소 억제제로 작용하는 1h-피라졸로[4,3-h]퀴나졸린 화합물 |
| CA3140030A1 (en) * | 2019-06-06 | 2020-12-10 | Arcus Biosciences, Inc. | Processes for preparing aminopyrimidine compounds |
| WO2021043190A1 (zh) * | 2019-09-05 | 2021-03-11 | 成都赛诺希亚生物科技有限公司 | 异噁唑并[5,4-h]喹唑啉类化合物作为蛋白激酶抑制剂 |
| WO2021084541A1 (en) * | 2019-10-31 | 2021-05-06 | Sol-Gel Technologies Ltd. | Treatment of hair loss disorders with a topical egfr inhibitor |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| CN116547280A (zh) * | 2020-10-08 | 2023-08-04 | 雷多纳治疗公司 | 用于治疗癌症的苯并[h]喹唑啉-4-胺和噻吩并[3,2-h]喹唑啉-4-胺衍生物 |
| WO2022111634A1 (zh) * | 2020-11-26 | 2022-06-02 | 成都赛璟生物医药科技有限公司 | 杂芳基并喹唑啉类化合物作为蛋白激酶抑制剂 |
| CN114685520B (zh) * | 2020-12-25 | 2024-08-30 | 武汉誉祥医药科技有限公司 | 三并环化合物及其药物组合物和应用 |
| CN116528871A (zh) * | 2020-12-31 | 2023-08-01 | 恒元生物医药科技(苏州)有限公司 | 一种吡唑并喹唑啉类化合物、其制备方法及应用 |
| CN116761806B (zh) * | 2021-02-08 | 2025-10-10 | 上海复星医药产业发展有限公司 | 5，6-二氢噻吩并[3，4-h]喹唑啉类化合物 |
| MX2024000022A (es) * | 2021-06-22 | 2024-03-15 | Taxis Pharmaceuticals Inc | Compuestos terapeuticos. |
| CN113527310B (zh) * | 2021-07-30 | 2022-09-23 | 上海市肺科医院 | 用于减轻自身免疫性疾病患者不良炎性反应的小分子化合物及其应用 |
| WO2023104178A1 (zh) * | 2021-12-10 | 2023-06-15 | 山东绿叶制药有限公司 | 蛋白激酶抑制剂及其制备方法和应用 |
| EP4653443A1 (en) * | 2023-01-17 | 2025-11-26 | Phil Rivers Technology Co., Ltd | Stereoisomer and deuterated derivative of pyrazoloquinazoline compound and use |
| WO2024251230A1 (zh) * | 2023-06-08 | 2024-12-12 | 山东绿叶制药有限公司 | 一种plk1激酶抑制剂的盐型、晶型及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2119975A (en) * | 1936-08-26 | 1938-06-07 | Beatrice S Nazel | Fluid pressure hammer |
| JP3907220B2 (ja) * | 1994-06-30 | 2007-04-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 複素環含有化合物 |
| JP3290666B2 (ja) | 1995-06-07 | 2002-06-10 | ファイザー・インコーポレーテッド | 複素環式の縮合環ピリミジン誘導体 |
| JP2001507349A (ja) | 1996-12-23 | 2001-06-05 | セルテック セラピューティックス リミテッド | 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用 |
| GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| BR0013143A (pt) | 1999-08-12 | 2002-06-11 | Pharmacia Italia Spa | Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais |
| CA2416527C (en) | 2000-08-10 | 2009-12-22 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| EP1309596B1 (en) * | 2000-08-11 | 2008-02-06 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| WO2002048114A1 (en) | 2000-11-27 | 2002-06-20 | Pharmacia Italia S.P.A. | Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
| WO2002070515A2 (en) | 2001-01-26 | 2002-09-12 | Pharmacia Italia Spa | Chromane derivatives, process for their preparation and their use as antitumor agents |
| CA2456939A1 (en) * | 2001-08-10 | 2003-02-20 | Pharmacia Corporation | Carbonic anhydrase inhibitors |
| US20030100594A1 (en) | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
| DE60238999D1 (de) | 2001-09-26 | 2011-03-03 | Pfizer Italia Srl | Aminoindazolderivate mit kinaseinhibierender wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen |
| MXPA04008130A (es) * | 2002-02-19 | 2004-11-26 | Pharmacia Corp | Derivados triciclicos de pirazol para el tratamiento de la inflamacion. |
| RS20050944A (sr) | 2003-05-22 | 2008-06-05 | Nerviano Medical Sciences S.R.L., | Derivati pirazolo- hinazolina,postupci za njihovo dobijanje i njihova upotreba kao inhibitora kinaze |
| SI2125822T1 (sl) * | 2006-12-21 | 2015-01-30 | Nerviano Medical Sciences S.R.L. | Substituirani pirazolo-kinazolinski derivati, postopek za njihovo pripravo in njihova uporaba kot inhibitorji kinaze |
-
2004
- 2004-04-27 RS YUP-2005/0944A patent/RS20050944A/sr unknown
- 2004-04-27 ES ES04741483.4T patent/ES2436524T3/es not_active Expired - Lifetime
- 2004-04-27 RS RS20050944A patent/RS52899B/sr unknown
- 2004-04-27 GE GEAP20049128A patent/GEP20094664B/en unknown
- 2004-04-27 EA EA200501849A patent/EA010904B1/ru unknown
- 2004-04-27 PT PT47414834T patent/PT1636236E/pt unknown
- 2004-04-27 MX MXPA05012573A patent/MXPA05012573A/es active IP Right Grant
- 2004-04-27 CN CNA2004800210752A patent/CN1826343A/zh active Pending
- 2004-04-27 BR BR122019010200A patent/BR122019010200B8/pt active IP Right Grant
- 2004-04-27 US US10/557,565 patent/US7482354B2/en not_active Expired - Lifetime
- 2004-04-27 WO PCT/EP2004/050612 patent/WO2004104007A1/en not_active Ceased
- 2004-04-27 OA OA1200500329A patent/OA13170A/fr unknown
- 2004-04-27 CN CN2010105863199A patent/CN102079746A/zh active Pending
- 2004-04-27 CA CA2526578A patent/CA2526578C/en not_active Expired - Lifetime
- 2004-04-27 EP EP04741483.4A patent/EP1636236B1/en not_active Expired - Lifetime
- 2004-04-27 AU AU2004240772A patent/AU2004240772B2/en not_active Expired
- 2004-04-27 AP AP2005003452A patent/AP2064A/xx active
- 2004-04-27 NZ NZ543661A patent/NZ543661A/xx not_active IP Right Cessation
- 2004-04-27 SI SI200432118T patent/SI1636236T1/sl unknown
- 2004-04-27 BR BRPI0410563A patent/BRPI0410563B8/pt not_active IP Right Cessation
- 2004-04-27 HR HRP20050967AA patent/HRP20050967B8/hr not_active IP Right Cessation
- 2004-04-27 KR KR1020057022355A patent/KR101084871B1/ko not_active Expired - Lifetime
- 2004-04-27 PL PL04741483T patent/PL1636236T3/pl unknown
- 2004-04-27 JP JP2006530168A patent/JP5043432B2/ja not_active Expired - Lifetime
- 2004-04-27 UA UAA200512347A patent/UA80763C2/uk unknown
- 2004-04-27 ME MEP-2008-259A patent/ME00142B/me unknown
- 2004-04-27 DK DK04741483.4T patent/DK1636236T3/da active
- 2004-05-04 TW TW093112449A patent/TWI349672B/zh not_active IP Right Cessation
- 2004-05-13 MY MYPI20041795A patent/MY142019A/en unknown
- 2004-05-20 AR ARP040101748A patent/AR044543A1/es active IP Right Grant
-
2005
- 2005-11-18 IS IS8132A patent/IS2939B/is unknown
- 2005-11-20 IL IL172046A patent/IL172046A/en active IP Right Grant
- 2005-11-21 NO NO20055496A patent/NO334992B1/no unknown
- 2005-11-21 TN TNP2005000298A patent/TNSN05298A1/fr unknown
- 2005-11-22 CO CO05118410A patent/CO5721006A2/es active IP Right Grant
- 2005-11-22 CR CR8102A patent/CR8102A/es unknown
- 2005-11-23 ZA ZA200509486A patent/ZA200509486B/xx unknown
- 2005-11-30 EC EC2005006194A patent/ECSP056194A/es unknown
-
2008
- 2008-10-31 US US12/262,933 patent/US8541429B2/en not_active Expired - Lifetime
-
2013
- 2013-08-21 US US13/972,659 patent/US8981089B2/en not_active Expired - Lifetime
- 2013-12-09 CY CY20131101108T patent/CY1114708T1/el unknown
-
2015
- 2015-02-18 US US14/625,093 patent/US9464090B2/en not_active Expired - Lifetime
- 2015-11-20 AR ARP150103780A patent/AR102722A2/es unknown
-
2016
- 2016-09-06 US US15/256,916 patent/US9637497B2/en not_active Expired - Fee Related
-
2017
- 2017-03-23 US US15/467,323 patent/US10280176B2/en not_active Expired - Lifetime
-
2019
- 2019-03-04 US US16/291,323 patent/US20190194214A1/en not_active Abandoned
-
2020
- 2020-10-30 US US17/084,862 patent/US20210300935A1/en not_active Abandoned
-
2023
- 2023-12-22 US US18/394,122 patent/US20250011333A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20055496L (no) | Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer | |
| NO20092737L (no) | Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer | |
| WO2005005414A3 (en) | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
| DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
| WO2009071480A3 (en) | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors | |
| ATE411022T1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
| ATE514699T1 (de) | Substituierte pyrrolopyrazolderivate als kinaseinhibitoren | |
| PH12013501594A1 (en) | Substituted indazole derivatives active as kinase inhibitors | |
| NO20045677L (no) | Inhibitorer av JAK- og CDK2-proteinkinaser | |
| NO20090443L (no) | 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater | |
| NO20030381L (no) | Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser | |
| NO20082065L (no) | Nye imidazo[4,5-b]pyridinderivater som inhibitorer av glykogensyntasekinase 3 for anvendelse ved behandling av demens og neurodegenerative forstyrrelser | |
| MX2009006401A (es) | Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer. | |
| NO20072259L (no) | Heteroaryltiazoler og deres anvendelse som P13K-inhibitorer | |
| NO20073140L (no) | Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser | |
| NO20071320L (no) | Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer. | |
| NO20060113L (no) | Pyrrolo(3,4-c)pyrazolderivater aktive som kinase inhibitorer | |
| NO20070514L (no) | Pyrrolotriazin kinase inhibitorer | |
| NO20053470L (no) | Triazolopyridaziner som proteinkinase-inhibitorer | |
| NO20025601L (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
| NO20040511L (no) | Aminoisoxazolderivater som kinaseinhibitorer | |
| WO2005014572A8 (en) | Pyrimidylpyrrole derivatives active as kinase inhibitors | |
| CY1108246T1 (el) | ΠΑΡΑΓΩΓΑ 1Η-ΘΕΙΕΝΟ[2,3-c] ΠΥΡΑΖΟΛΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΗΣ | |
| UA102219C2 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы | |
| TW200502236A (en) | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents |